| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12253-015-9916-9 |
| P698 | PubMed publication ID | 25749811 |
| P50 | author | Christine Pirker | Q58330483 |
| Viktoria Laszlo | Q58880202 | ||
| Balázs Hegedűs | Q39031785 | ||
| Walter Berger | Q39186773 | ||
| Michael Grusch | Q39813444 | ||
| P2093 | author name string | József Tímár | |
| Tamás Barbai | |||
| Judit Dobos | |||
| Éva Juhász | |||
| Eszter Molnár | |||
| Karin Schelch | |||
| Tamás Garay | |||
| P2860 | cites work | The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis | Q24312466 |
| Receptor specificity of the fibroblast growth factor family | Q24320178 | ||
| AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance | Q24648017 | ||
| Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family | Q24676527 | ||
| Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis | Q24791830 | ||
| Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects | Q26825703 | ||
| BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy | Q27650860 | ||
| Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase | Q27674360 | ||
| NRAS mutation status is an independent prognostic factor in metastatic melanoma | Q27851695 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Determinants of BRAF mutations in primary melanomas | Q28191720 | ||
| FGF receptors: cancer biology and therapeutics | Q28291186 | ||
| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity | Q29547693 | ||
| Distinct sets of genetic alterations in melanoma | Q29614965 | ||
| Cellular signaling by fibroblast growth factors (FGFs) and their receptors (FGFRs) in male reproduction | Q30439922 | ||
| Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors | Q33396953 | ||
| Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation | Q33626287 | ||
| Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib | Q33821320 | ||
| Autocrine and paracrine regulation by cytokines and growth factors in melanoma | Q33937586 | ||
| EGF receptor ligands | Q34185050 | ||
| Regulation of the Ras signalling network | Q34324610 | ||
| The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis | Q34442771 | ||
| Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma | Q34520671 | ||
| Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting | Q34611953 | ||
| A phase II study of gefitinib in patients with metastatic melanoma | Q35093992 | ||
| Cellular responses to EGFR inhibitors and their relevance to cancer therapy | Q36003118 | ||
| Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition | Q36059811 | ||
| The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma | Q36170391 | ||
| Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes. | Q36219364 | ||
| FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients | Q36614414 | ||
| The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo. | Q50510432 | ||
| Cell migration or cytokinesis and proliferation?--revisiting the "go or grow" hypothesis in cancer cells in vitro. | Q53093213 | ||
| Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. | Q53391786 | ||
| Expression of a decorin-like moleculein human melanoma. | Q53391833 | ||
| Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines. | Q54189587 | ||
| BRAF mutations in metastatic melanoma: a possible association with clinical outcome. | Q54756359 | ||
| Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation | Q67935567 | ||
| Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth | Q73585686 | ||
| EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis | Q80534199 | ||
| Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma | Q85049476 | ||
| Epidermal growth factor facilitates melanoma lymph node metastasis by influencing tumor lymphangiogenesis | Q95407241 | ||
| Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma | Q36982042 | ||
| Targeting the RAS pathway in melanoma | Q37137004 | ||
| Genetics and genomics of melanoma | Q37409032 | ||
| Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma | Q37660341 | ||
| Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? | Q37697006 | ||
| Receptor tyrosine kinases and their activation in melanoma. | Q37841746 | ||
| Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy. | Q37849781 | ||
| Anticancer molecules targeting fibroblast growth factor receptors | Q38033867 | ||
| Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma | Q39325740 | ||
| AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family | Q39389469 | ||
| Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models | Q39413387 | ||
| Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways | Q39431960 | ||
| EGFR in melanoma: clinical significance and potential therapeutic target | Q39586032 | ||
| Erlotinib and bevacizumab have synergistic activity against melanoma | Q39850335 | ||
| ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839). | Q39852895 | ||
| Fibroblast growth factor-2 modulates melanoma adhesion and migration through a syndecan-4-dependent mechanism. | Q39901293 | ||
| Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide | Q39905603 | ||
| Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma. | Q40005196 | ||
| Irradiation and Taxol treatment result in non-monotonous, dose-dependent changes in the motility of glioblastoma cells | Q40568796 | ||
| Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade | Q40629608 | ||
| Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor | Q40822228 | ||
| Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes | Q40912266 | ||
| Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: evidence for the involvement of Src-family kinases | Q41103907 | ||
| Novel and known protein tyrosine kinases and their abnormal expression in human melanoma | Q41517148 | ||
| Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth factor receptor | Q41687505 | ||
| Transformation of murine melanocytes by basic fibroblast growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment | Q41760172 | ||
| Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study | Q43013821 | ||
| Regulation of epidermal growth factor receptor expression in human melanocytes | Q43758715 | ||
| A novel role for FAK as a protease-targeting adaptor protein: regulation by p42 ERK and Src. | Q44558581 | ||
| Outcomes of patients with metastatic melanoma treated with molecularly targeted agents in phase I clinical trials | Q44932310 | ||
| Monoclonal antibodies targeting basic fibroblast growth factor inhibit the growth of B16 melanoma in vivo and in vitro. | Q45301823 | ||
| Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor. | Q47746353 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 957-968 | |
| P577 | publication date | 2015-03-09 | |
| P1433 | published in | Pathology Oncology Research | Q26842743 |
| P1476 | title | Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations. | |
| P478 | volume | 21 |
| Q92544513 | Fibroblast Growth Factor Receptor Signaling in Skin Cancers |
| Q38821729 | Microfluidic co-cultures with hydrogel-based ligand trap to study paracrine signals giving rise to cancer drug resistance |
| Q97550415 | Perturbation biology links temporal protein changes to drug responses in a melanoma cell line |
| Q48133801 | Phenytoin enhances the phosphorylation of epidermal growth factor receptor and fibroblast growth factor receptor in the subventricular zone and promotes the proliferation of neural precursor cells and oligodendrocyte differentiation. |
| Q89522269 | Sialylation of FGFR1 by ST6Gal‑I overexpression contributes to ovarian cancer cell migration and chemoresistance |
| Q41243255 | Uncarboxylated Osteocalcin Induces Antitumor Immunity against Mouse Melanoma Cell Growth |
Search more.